OptiLeukin 2 – Data Sheet
Download the OptiLeukin 2 Data Sheet for a clear, high-level overview of this recombinant human IL-2, including product details, key features, benefits, and applications.
Month: April 2025
Sustained T Cell Proliferation and Early Memory Retention with OptiLeukin™ 2 Recombinant IL-2
Key Points InVitria’s OptiLeukin™ 2, a high-purity (≥ 98%), GMP-grade, recombinant human interleukin-2 (IL-2) enables robust expansion of primary T cells. OptiLeukin 2 supports the generation of T cells with a favorable memory phenotype, essential for long-term therapeutic persistence. OptiLeukin 2 matches the performance of leading GMP IL-2 products, enabling a seamless like-kind replacement. OptiLeukin …
InVitria Launches OptiLeukin 2 Recombinant Interleukin-2
InVitria® Launches OptiLeukin™ 2: A Chemically Defined, Animal- and Bacteria-Free Recombinant IL-2 for Immune Cell Manufacturing Junction City, KS – April 21, 2025 – InVitria®, a leading provider of recombinant, chemically defined biomanufacturing and formulation components, today announced the launch of OptiLeukin™ 2, a high-purity, animal- and bacteria-free recombinant human interleukin-2 (IL-2) designed for immune …
Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel
Reading time: 4 minutes Share this article: Cancer cells have a sneaky habit. Just when it seems chemotherapy is getting the upper hand, they adapt, pumping drugs out faster than they come in. It’s called multidrug resistance (MDR), and it’s a major roadblock in treating cancers like breast, lung, and pancreatic. But what if …